Survodutide

Key benefits

What to expect

Based on community reports and published research. Individual results vary significantly.

Dosing protocols

Dosing information is sourced from published research and community protocols. This is not a recommendation. Consult a healthcare professional.

Overview

Survodutide activates both GLP-1 and glucagon receptors, similar to mazdutide. What sets it apart is its clinical data in MASH (formerly NASH), the fatty liver disease affecting millions worldwide. In a Phase 2 trial, survodutide achieved MASH resolution without worsening fibrosis in up to 83% of patients at the highest dose, along with approximately 19% weight loss. The dual-agonist approach is particularly suited to liver disease because glucagon receptor activation directly promotes hepatic fat oxidation. Boehringer Ingelheim is advancing it into Phase 3 trials for both obesity and MASH.

How it works

Survodutide activates GLP-1 receptors (reducing appetite, slowing gastric emptying, improving insulin secretion) and glucagon receptors (increasing hepatic fat oxidation, boosting energy expenditure, promoting glycogenolysis). The glucagon component is what drives the liver-specific benefits: glucagon directly stimulates the liver to burn stored fat, addressing the root cause of MASH.

Side effects

Research history

Recommended products

Hand-picked for this compound. Ships via Amazon 🇺🇸

References

1. [1]Sanyal AJ, et al. 'Survodutide, a dual glucagon receptor/GLP-1 receptor agonist, for treatment of MASH.' New England Journal of Medicine, 2024.

Frequently asked questions

Related peptides